Upcoming news

Views : 131
Author : Banly Li
Update time : 2023-10-08 11:24:29
Related News
Jinquan's highlight Jinquan's highlight
Oct .27.2023
Jinquan first international exhibition Medlab Middle East Dubai

We Guangdong Jinquan medical spends a lot of money on R&D, lots of internatinal business though, never participated in international exhibition.
Hereafter excited to share this stunning news here.
Explore the world and create medical innovation together - Guangdong Jinquan's first international medical exhibition in 2024. We are waiting for you in Dubai!
Dear partners:
We Jinquan is going to attend the Dubai Arab International Laboratory Instruments and Equipment Exhibition (Medlab Middle East 2024), an internationally well-known medical device leading event! Participating in this exhibition will be an important milestone for our company and an excellent opportunity for us to showcase our latest research &development, and technical strengths to the world.
As an enterprise dedicated to the research and development of pathological medical devices, we always adhere to the mission "Servicing Human Being Life and Health" and continuously promoted the process of
medical innovation. Through continuous R&D and innovation, we have updated a series of high-quality pathological medical devices to meet the growing needs for hospital units, diagnostics labs, research labs...
At this exhibition, we will showcase our industry-leading devices to the world: fully automated block&slide QR code batch scanners, UV laser cassette printer, UV laser slide printer, tissue rapid freezers, etc. The launch of these instruments not only increases pathologists’ workflow efficiency and accuracy, avoiding potential misidentify errors, but also injects new elements into the development of hospitals and laboratories.
How important to stay competitive by keeping on a continuous pursuit and innovation of technology in such increasingly fierce competition and ever-changing medical field. By cooperating with many well-known domestic pathological medical research institutes, we continue to deeper learn the latest scientific research results and constantly advance with market trends, and develop them into medical equipment with high performance practical utility.
We are excited and look forward to deeply communicating with you and together exploring the new directions of medical innovation.
Jinquan Booth No.: Z2 A11
Exhibition location: Dubai United Arab Emirates
Exhibition time: 5-8 February 2024
As a technology R&D driven company, we are continuously  committed to providing better pathological medical devices and solutions to medical institutes around the world. We firmly believe that through our unremitting efforts and continuous innovation, we can bring more advanced medical products to the world.
Thank you for your continued support and trust in us. See you in Medlab Middle East exhibition, and can’t wait to expect your visit and constructive suggestions.
Guangdong Jinquan Medical Technology Co., Ltd.
President to address Global Health Summit President to address Global Health Summit
May .21.2021
President Xi Jinping will take part in the Global Health Summit on Friday via video link from Beijing, joining leaders of the Group of 20 members and heads of international and regional organizations in efforts to boost global cooperation in the fight against the COVID-19 pandemic.Xi will deliver a speech at the event, which will take place at Villa Pamphilj in Rome.
The summit was organized by Italy, the holder of the G20 presidency, in partnership with the European Commission.
Sanofi, GlaxoSmithKline report positive trial results of COVID-19 vaccine Sanofi, GlaxoSmithKline report positive trial results of COVID-19 vaccine
May .18.2021
A COVID-19 vaccine from drugmakers Sanofi and GlaxoSmithKline produced antibody responses on par with those who experienced natural infection, the companies said in early clinical results, paving the way for a late-stage trial in the coming weeks.

The companies said the recombinant DNA vaccine exhibited no safety problems in a randomized, double-blind study involving more than 700 people ages 18 and older in the U.S. and Honduras.